Wang, ZhiranZhiranWangZhernovkov, VadimVadimZhernovkovDmitrii, LebedevLebedevDmitriiWu, KevinKevinWuDoyle, LorcanLorcanDoyleWynne, KieranKieranWynneBlanco-Fernandez, AlfonsoAlfonsoBlanco-FernandezMysior, Margaritha M.Margaritha M.MysiorSimpson, Jeremy C.Jeremy C.SimpsonWülfroth, PetraPetraWülfrothLi, SimengSimengLiKolch, WalterWalterKolchEissner, GüntherGüntherEissner2025-04-042025-04-042024-09-02http://hdl.handle.net/10197/27872The 7th European Congress of Immunology, Dublin, Ireland, 1-4 September 2024Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a major health emergency since 2019. Endothelial dysfunction is a hallmark of COVID-19, which leads to severe illness, i.e. multi-organ failure, coagulopathy, and death. FX06, a fibrin-derived peptide naturally occurring in the human body, formerly known as Bβ15-42, protects the vasculature in myocardial ischemia-reperfusion in animal models and clinical trials. Therefore, it is a promising therapeutic candidate for endothelial complications like capillary leak in COVID-19 and other forms of acute respiratory disorders. This project aims to investigate in vitro whether FX06 can help to prevent COVID-19 progression.enCoronavirusCOVID-19SARS-CoV-2Endothelial dysfunctionFX06In vitro assayConference Publication2024-07-25101045956https://creativecommons.org/licenses/by-nc-nd/3.0/ie/